|
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: Analysis of the STAR TOR registry. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Ipsen; Pfizer |
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Ipsen; Pfizer; Roche |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Roche |
Travel, Accommodations, Expenses - Ipsen |
|
|
|
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi |
Research Funding - Janssen-Cilag |
Travel, Accommodations, Expenses - Amgen; Bayer; Janssen-Cilag |
|
|
Honoraria - Amgen; Eisai; Ipsen; Roche |
Consulting or Advisory Role - Amgen; Eisai; EUSA Pharma; Ipsen; Novartis; Roche |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen-Cilag; Merck Serono; Pfizer; Sanofi |